Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Jens, Bedke"'
Autor:
Marcus Scharpf, Jens Bedke, Silvia Ribback, Manuela Gellert, Nils Kroeger, Stefan Winter, Elke Schaeffeler, Matthias Schwab, Viktoria Stühler, Christopher Horst Lillig, Tobias Klatte, Martin Burchardt
Publikováno v:
World journal of urology. 40(3)
Purpose Thioredoxins are major regulatory proteins of oxidative signaling. Trx1 is the most prominent thioredoxin and, therefore, the current study sought to evaluate the prognostic role of Trx1 in ccRCC. Methods and patients A tissue micro-array (TM
Autor:
Jens Bedke, Judith Wahrheit, Marcus Scharpf, Anna Reustle, Matthias Schwab, Elke Schaeffeler, Abbas Agaimy, Arndt Hartmann, Verena Klumpp, Steffen Rausch, Arnulf Stenzl, Stefan Winter, Pascale Fisel, Florian Büttner, Falko Fend, Jörg Hennenlotter, Denise Sonntag, Stephan Kruck
Publikováno v:
European Urology Focus. 5:608-618
Background Renal cell carcinoma (RCC) consists of prognostic distinct subtypes derived from different cells of origin (eg, clear cell RCC [ccRCC], papillary RCC [papRCC], and chromophobe RCC [chRCC]). ccRCC is characterized by lipid accumulation and
Autor:
Pascale Fisel, Jörg Hennenlotter, Anne T. Nies, Stephan Kruck, Florian Büttner, Jens Bedke, Falko Fend, Elke Schaeffeler, Arnulf Stenzl, Marcus Scharpf, Stefan Winter, Olga Renner, Anna Reustle, Steffen Rausch, Matthias Schwab
Publikováno v:
International Journal of Cancer. 143:3181-3193
The efflux transporter breast cancer resistance protein BCRP/ABCG2 is well-known for its contribution to multi-drug resistance in cancer. Its relevance in cancer biology independent from drug efflux remains largely elusive. Our study aimed at elucida
Autor:
Susanne Krege, Christian Doehn, Peter J. Goebell, Viktor Gruenwald, Gunhild von Amsberg, Dominik Berthold, Philipp Ivanyi, Marc-Oliver Grimm, Lothar Bergmann, Jens Bedke, Jonas Busch, Margitta Retz, Martin Boegemann
Publikováno v:
Future oncology (London, England). 16(29)
The therapy of advanced (clear-cell) renal cell carcinoma (RCC) has recently experienced tremendous changes. Several new treatments have been developed, with PD-1 immune-checkpoint inhibition being the backbone of therapy. Diverse immunotherapy combi
Autor:
Satoshi Tamada, Dmitry Nosov, Thomas K. Waddell, Rustem Gafanov, Raymond S. McDermott, L Rhoda Molife, J. Burgents, Chenxiang Li, Viktor Stus, Thomas Powles, Elizabeth R. Plimack, Delphine Borchiellini, Bohuslav Melichar, Frédéric Pouliot, Jens Bedke, Ihor Vynnychenko, Denis Soulières, Sergio J Azevedo, Brian I. Rini, Anna Kryzhanivska
Publikováno v:
Journal of Clinical Oncology. 39:4500-4500
4500 Background: In the first interim analysis of the randomized, multicenter, open-label, phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro + axi significantly improved OS, PFS, and ORR vs sunitinib monotherapy in treatment-naive advanc
Autor:
Jörg Hennenlotter, Steffen Rausch, Stephan Kruck, Falko Fend, Jens Bedke, Arnulf Stenzl, Marcus Scharpf, Anne T. Nies, Matthias Schwab, Viktoria Stühler, Pascale Fisel, Elke Schaeffeler, Stefan Winter
Publikováno v:
Oncotarget
// Pascale Fisel 1,2,* , Viktoria Stuhler 3,* , Jens Bedke 3,4,* , Stefan Winter 1,2 , Steffen Rausch 3 , Jorg Hennenlotter 3 , Anne T. Nies 1,2 , Arnulf Stenzl 3,4 , Marcus Scharpf 5 , Falko Fend 5 , Stephan Kruck 3 , Matthias Schwab 1,2,4,6 and Elk
Autor:
Steffen Rausch, Joerg Hennenlotter, Jens Bedke, Daniel Schollenberger, Stephan Kruck, Arnulf Stenzl, Viktoria Stühler
Publikováno v:
Journal of cancer research and clinical oncology. 145(1)
Impaired regulation of the Akt/mammalian target of rapamycin (mTOR) pathway has been implicated in mechanisms related to neoplastic transformation in renal cell cancer (RCC) through enhancement of cell proliferation and survival and mTOR activation h
Autor:
Steffen Rausch, Jörg Hennenlotter, Matthias Schwab, Marcus Scharpf, Stephan Kruck, Elke Schaeffeler, Eva Neumann, Peter Klaiber, Jens Bedke, Arnulf Stenzl, Falko Fend, Kathleen Freitag
Publikováno v:
Journal of Urology. 199
Autor:
Ingmar Blümcke, Bastian Gunawan, Ralf Schober, Kathy Keyvani, Michael Buchfelder, Henry W. S. Schroeder, László Füzesi, Marlis Günther, Hansdetlef Wassmann, Martin Nischwitz, Werner Paulus, Wolfgang Stummer, Alf Giese, Klaus Jung, Veit Rohde, Jürgen Meixensberger, Angelika Gutenberg, Ulrich Sure, Rupert Egensperger, Christina Enders, Jens Bedke, Wolfgang Brück, Rolf Warzok, Bjoern Sander, Peter Vajkoczy, Frank van Landeghem, Wolfgang Feiden, Markus Bergmann, Dietmar Stolke
Publikováno v:
Gutenberg, A, Nischwitz, M D, Gunawan, B, Enders, C, Jung, K, Bergmann, M, Feiden, W, Egensperger, R, Keyvani, K, Stolke, D, Sure, U, Schroeder, H W S, Warzok, R, Schober, R, Meixensberger, J, Paulus, W, Wassmann, H, Stummer, W, Blumcke, I, Buchfelder, M, van Landeghem, F K H, Vajkoczy, P, Günther, M, Bedke, J, Giese, A, Rohde, V, Brück, W, Füzesi, L & Sander, B 2014, ' Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma ', Cancer genetics and cytogenetics, vol. 207, no. 5, pp. 206-213 . https://doi.org/10.1016/j.cancergen.2014.05.004
Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and clus
Autor:
Karl-Dietrich Sievert, David Schilling, Axel S. Merseburger, Stephan Kruck, Marcus Scharpf, Kathrin Kasprzyk, Arnulf Stenzl, Jens Bedke, Felix K.-H. Chun
Publikováno v:
BJU International. 110:E771-E777
What's known on the subject? and What does the study add? White blood cell count and C-reactive protein are reliable prognostic RCC Biomarkers.Nevertheless, accepted cut-offs for risk stratifications are missing. Therefore, both parameters were re-ev